CXCL9 and neoplasm: Importantly, NPTyr-C9AP treatment increased the percentages of tumor-infiltrating CD3+ T cells to 21.7% of CD45+ lymphocytes due to the synergistic effects of intratumoral expression of CXCL9 and αPD-L1.